|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
L-type amino acid transporter 1 (LAT1) and CD98 are frequently expressed in various human cancers, and closely correlated with tumor aggressiveness and survival.
|
28052681 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this study was to study the distribution of two LAT1-targeting PET tracers, L-4-borono-2-<sup>18</sup>F-fluoro-phenylalanine (<sup>18</sup>F-FBPA) and L-3-<sup>18</sup>F-alpha-methyl tyrosine (<sup>18</sup>F-FAMT), in relation to the tumor blood flow, using rat xenograft models.
|
30820863 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LAT1 expression increases as cancers progress, leading to higher expression levels in high-grade tumors and metastases.
|
31376820 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Amino acid transporters are necessary for tumor growth, metastasis, and survival of various neoplasms; however, the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and 4F2 cell surface antigen (4F2hc) in patients with pulmonary pleomorphic carcinoma (PPC) remainsunknown.
|
30300664 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of LAT1 was identified as an independent significant marker linked to worse prognosis in patients with CRC, and was correlated with tumor cell proliferation, tumor aggressiveness, and metastasis.
|
31092450 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A genetically engineered mouse model of ATC was used to address the effect of blocking LAT1 on tumor growth in vivo.
|
30241549 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
|
29326164 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SLC7A5 mRNA and protein expression was significantly associated with the expression of the key regulator of tumour cell metabolism, c-MYC, specifically in luminal B tumours only (p = 0.001).
|
29566741 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mRNA expression levels of the amino acid transporters of system A (SLC38A1 and SLC38A2), system L (SLC7A5) and system ASC (SLC1A5) were higher in all eight tumors than in the normal lung, with widely varying expression patterns.
|
30334568 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high expression of LAT1 protein was significantly associated with tumor differentiation, tumor depth (T factor), lymph node metastasis, venous invasion, recurrence, and clinical response.
|
29149426 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Orthotropic C6 and U87 tumors were clearly visualized with high tumor to brain ratios at 60 min post-injection, corroborating with tumor L-type amino acid transporter 1 (LAT-1) expression levels.
|
29285548 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
L-type amino acid transporter 1 (LAT1) has an essential role in cell proliferation especially in neoplasms.
|
28370814 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LAT1 protein was expressed in 15 out of 16 (93.75%) SDHx tumors, regardless of the <sup>18</sup>F-FDOPA positivity.
|
27900521 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor sections were stained and analyzed using immunohistochemistry to assess CD98 expression.
|
28179310 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The LAT1 targeting nanoparticles exhibited better tumor accumulation and antitumor effects.
|
27890657 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate a requirement for CD98 in EC growth and suggest that CD98-specific reagents could have a dual anticancer effect: directly by inhibiting tumor cell proliferation and indirectly by preventing tumor angiogenesis.
|
27687603 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This recycling process for basigin and CD98 promotes cell spreading and tumor growth in liver cancer xenografts.
|
26437640 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The gene (SLC7A5) encoding system L amino-acid transporter 1 (LAT1) is overexpressed in murine lymphoma cells generated via T-cell deletion of the pten tumor suppressor, and also in human T-cell acute lymphoblastic leukemia (T-ALL)/lymphoma (T-LL) cells.
|
25482130 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Prognosis tended to be worse in patients having tumors with LAT1-high/LAT2-low than LAT1-low/LAT2-high scores (P = 0.0686).
|
24890221 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High LAT1 expression in HCC was associated significantly with tumor size (P = 0.032), histological differentiation (P = 0.003), and tumor stage (P = 0.01).
|
23696029 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased expression of LAT1 mRNA was associated with less differentiated tumors, local invasion, microscopic vascular invasion, and metastasis.
|
24168110 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The correlation between tumour uptake of (18)F-FAMT and L-type amino acid transporter 1 (LAT1) expression was determined.
|
23801167 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the role of the HAT 4F2hc/LAT1 in tumor growth and the application of LAT1 inhibitors and PET tracers for reduction of tumor progression and imaging of tumors are discussed.
|
23506863 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression characteristic of LAT-1 in GC was significantly associated with clinicopathologic features such as tumor size, lymph node metastasis, local invasion and TNM stage.
|
23809372 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the CD98(high) subpopulation expresses high levels of cell cycle control and DNA repair genes, while the CD98(low) fraction shows expression patterns that represent the more differentiated cells forming the bulk of the tumor.
|
23523931 |
2013 |